CutisPharma Announces Launch of Two New Compounding Kit Families..
WILMINGTON, Mass. (October 3, 2016) – CutisPharma, a specialty pharmaceutical company that develops and distributes kits used by pharmacists to safely create compounded medications, has expanded its product portfolio to include FI℞ST® Unit-of-Use Prescription Compounding Kits for Metronidazole and Baclofen oral suspensions, two medications that pharmacists are often called upon to compound for young and elderly patients who have difficulty using commercially available versions of the drug.
FI℞ST® – Metronidazole allows pharmacists to prepare a grape-flavored suspension in either 50mg/mL or 100mg/mL strengths for patients needing an oral suspension formulation of this therapy.
FI℞ST® – Baclofen enables the preparation of a grape-flavored suspension in 1 and 5 mg/mL strengths.
The kits each have pre-measured powder and diluent that the pharmacist combines into a suspension, negating the need for any weighing, measuring or stirring. The kits, manufactured in an FDA-registered, cGMP pharmaceutical facility, facilitate pharmacist compliance with Section 503A of the Food, Drug, and Cosmetic Act and USP <795> standards governing pharmacy compounding.
With these new product additions, CutisPharma now produces 29 kits, which are carried by all major retail chain pharmacies, leading hospitals and long term care facilities, and independent pharmacies.
CutisPharma, Inc., based in Wilmington, Mass., is a privately held, specialty pharmaceutical company that has been an innovation leader in the pharmaceutical compounding market, developing kits used by pharmacists to safely create compounded medications. Building on the strength of its FI℞ST® Unit-of-Use kit portfolio, the company has expanded its focus toward developing and commercializing FDA-approved drugs in niche markets of high-unmet need. For more information, visit www.cutispharma.com.